ROS1 and breast carcinoma: The patient with the most actionable alterations had four actionable alterations, including BRCA loss, CCND1 amplification, PI3KCA base substitutions and the novel ROS1–EPHA7 fusion that was identified in breast cancer tumours for the first time.